Bosh sahifaMLLCF • OTCMKTS
add
Molecular Partners AG
Yopilish kursi
4,53 $
Yillik diapazon
3,66 $ - 10,14 $
Bozor kapitalizatsiyasi
239,77 mln USD
Oʻrtacha hajm
28,00
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
SWX
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (CHF) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 681,00 ming | -73,20% |
Joriy xarajat | 4,41 mln | -0,38% |
Sof foyda | -16,40 mln | -43,40% |
Sof foyda marjasi | -2,41 ming | -435,08% |
Har bir ulushga tushum | -0,49 | — |
EBITDA | -14,00 mln | -8,64% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (CHF) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 143,62 mln | -30,49% |
Jami aktivlari | 154,21 mln | -29,30% |
Jami passivlari | 15,43 mln | -29,56% |
Umumiy kapital | 138,78 mln | — |
Tarqatilgan aksiyalar | 33,19 mln | — |
Narxi/balansdagi bahosi | 1,08 | — |
Aktivlardan daromad | -22,46% | — |
Kapitaldan daromad | -24,30% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (CHF) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -16,40 mln | -43,40% |
Operatsiyalardan naqd pul | -13,28 mln | -0,68% |
Sarmoyadan naqd pul | 14,22 mln | -20,00% |
Moliyadan naqd pul | -301,00 ming | -1,01% |
Naqd pulning sof oʻzgarishi | 66,00 ming | -98,72% |
Boʻsh pul | -8,09 mln | -4,19% |
Haqida
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Tashkil etilgan
2004
Xodimlar soni
162
